Tyme Technologies

TYME Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Express

Express Inc (NYSE:EXPR) and Tyme Technologies Inc (NASDAQ:TYME) skyrocketed in January and February after gaining the attention of the WallStreetBets community. Now known as meme stocks, along with GameStop (NYSE:GME) and AMC Entertainment Holdings Inc (NYSE:AMC) and dozens of others, Express and Tyme fell into long periods of consolidation after soaring 1,078% and 202%, respectively.

2 Meme Stocks Test Resistance For A Larger Move

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that it has appointed Frank L. Porfido as its Chief Financial Officer, effective shortly after the Company files its annual report on Form 10-K. Mr. Porfido is a well-established biotech and pharmaceutical industry executive with over 25 years of strategic financial leadership expertise. Thro

TYME Appoints Frank L. Porfido as Chief Financial Officer

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its abstract featuring data from the Company's investigational therapy, SM-88, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually June 4-8, 2021. Details about the abstract selected for publication can be found below:

TYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual Meeting

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr. Van Tornout will provide leadership and direction for all medical and related preclinical programs in development. He will be replacing Dr. Giuseppe Del Priore. “On behalf of the board of directors, we truly ap

TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer

The company closed a $100 million public stock offering.

Why Tyme Technologies Stock Is Taking Off Today

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it closed its previously announced registered direct offering of 40,000,000 shares of its common stock, par value $0.0001 per share, at a purchase price of $2.50 per share, priced at-the-market under Nasdaq rules. The gross proceeds of the offering were $100 million, prior to deducting placement agent's fees and

TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock

The clinical-stage biotech provides investors with a quarterly update.

Why Tyme Stock Got Demolished Today

The stock price of Tyme Technologies Inc (NASDAQ: TYME) is trading down over 25% pre-market as of 8:15 AM ET. This is why it happened.

TYME Stock Price Falls Over 25% Pre-Market: Why It Happened

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third quarter ended December 31, 2020. During the quarter, TYME continued to build its leadership team with the announcement of Richie Cunningham as the new CEO; the Company continued to grow its global patent portfolio; expanded its body of peer-reviewed data presentations on SM-88 (

TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results

Tyme Technologies Inc (NASDAQ: TYME) has announced the sale of 40 million shares at $2.50 per share in the registered direct offering, with gross proceeds of $100 million. The offering is expected to close by February 8. TYME's closing price as of Wednesday was $3.53.

Tyme Technologies Shares Dive On $100M Equity Offering

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), today announced that it has entered into definitive agreements with several healthcare-focused institutional and other institutional investors for the sale of an aggregate of 40,000,000 shares of its common stock at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq Rules. The offer

TYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

The stock price of Tyme Technologies Inc (NASDAQ: TYME) is trading at over 100% today. This is why it happened.

TYME Stock Price Increases Over 100%: Why It Happened

Tyme Technologies skyrocketed as much as 127% on Wednesday after the company announced the US Patent and Trademark Office granted additional patent claims for their product TYME-19—a metabolomic technology directed at treating COVID-19. As an emerging biotechnology company, Tyme Technologies usually focuses on developing treatments for advanced cancers through its cancer metabolism-based therapies called CMBTs™.

Tyme Technologies skyrockets 120% after securing new patent claims for Covid-19 infection fighting technology (TYME)

The U.S. Patent and Trademark Office is on Tyme's side.

Why Tyme Technologies Stock Is Crushing It Today

Tyme Technologies Inc (NASDAQ: TYME) shares are nearly doubling on above-average volume Wednesday. Tyme, which focuses on developing cancer metabolism-based therapies, said the U.S. Patent and Trademark Office has granted additional patent claims related to its metabolomic technology platform.

Why Tyme Technologies Shares Are Surging Higher

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company's metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19. Unlike immune therapies that depend upon the structure of t

TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections

Revisiting Tyme Technologies

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an abstract highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer, has been selected for poster presentation at the American Society of Clinical Oncology (ASCO) Virtual 2021 Gastrointestinal Cancers Symposium being held on January 15 - 17, 2021.

TYME Announces SM-88 Abstract Selected for Presentation at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that, effective November 24, 2020, Steve Hoffman will remain in the role of Chairman of the board of directors and continue as the Company's Chief Science Officer, after a successful tenure as Chief Executive Officer since 2015. Richie Cunningham, former Icagen CEO and Boehringer Ingelheim executive, has been appointed as

TYME Builds Leadership Team with Announcement of New CEO

In this article we are going to use hedge fund sentiment as a tool and determine whether Tyme Technologies, Inc. (NASDAQ:TYME) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of news stories covering failed hedge fund investments and it is a fact that hedge funds' picks don't beat the market 100% of the time, but their consensus picks have historically done very well and have outperformed the market after adjusting for risk.

Is Tyme Technologies, Inc. (TYME) Going to Burn These Hedge Funds?

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its second quarter ended September 30, 2020. During the quarter, TYME revealed a potential new therapeutic approach in the fight against COVID-19; was granted orphan drug designation for SM-88 as a potential treatment for patients with pancreatic cancer; expanded its body of peer-reviewed

TYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating Results

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (race

Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020

TYME Technologies: My Bamboo Speculation In A Potential Leader In Cancer Metabolism-Based Therapies.

Tyme has a solid product candidate in pancreatic cancer.

Tyme Technologies: Killing Cancer By Compromising Tumor Cell Metabolism

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

TYME’s Phase II Prostate Cancer Study Evaluating SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published in the Journal, Investigational New Drugs

News for Tyme Technologies Stock (TYME)